Form 4: Wave Life Sciences Director Sells Shares

Wave Life Sciences Director Christian O. Henry executed a series of option exercises and subsequent sales of ordinary shares totaling 93,445 shares on December 8, 2025, under a Rule 10b5-1 trading plan.

Summary

• Director Christian O. Henry engaged in multiple transactions involving Wave Life Sciences Ltd. ordinary shares on December 8, 2025.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.
• Exercised options to acquire 42,000 ordinary shares at an exercise price of $5.97 per share.
• Sold 42,000 ordinary shares at a weighted-average sale price of $12.75 per share.
• Exercised options to acquire 15,000 ordinary shares at an exercise price of $3.50 per share.
• Sold 15,000 ordinary shares at a weighted-average sale price of $14.07 per share, with individual sales ranging from $14.00 to $14.14.
• Exercised options to acquire 30,000 ordinary shares at an exercise price of $4.585 per share.
• Sold 30,000 ordinary shares at a weighted-average sale price of $18.02 per share, with individual sales ranging from $18.00 to $18.19.
• An additional 6,445 ordinary shares were sold at $12.75 per share.
• Following these reported transactions, beneficial ownership of ordinary shares held directly by Christian O. Henry is 12,700.
• Remaining derivative securities include 6,000 share options with an exercise price of $3.50 and 15,000 share options with an exercise price of $4.585, all of which are fully vested.

Sentiment

Score: 4

Explanation: The director's sale of a significant number of shares, even under a pre-arranged 10b5-1 plan, can be perceived as a slight negative as it reduces insider ownership. However, the transactions represent the realization of gains from vested options, which is a common practice for executives.

Positives

• Director Christian O. Henry realized significant gains by exercising options at lower prices ($3.50, $4.585, $5.97) and selling the acquired shares at higher market prices ($12.75, $14.07, $18.02).
• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to managing equity rather than an immediate reaction to new, non-public information.

Negatives

• Director Christian O. Henry significantly reduced direct beneficial ownership of ordinary shares from a higher amount to 12,700 shares following the sales.
• A total of 93,445 ordinary shares were disposed of through sales, which can be perceived as a reduction in insider conviction, even if pre-planned.

Future Outlook

NA

Management Comments

• The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.
• These share options are fully vested.
• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider selling as a slight negative signal, though mitigated by the 10b5-1 plan. Could lead to short-term price volatility or increased scrutiny.

Key Dates

Recommendation

The director's sale of shares, while significant, was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests the transactions were not based on new, non-public information. This mitigates the typical negative signal of insider selling. The director is realizing gains from vested options. Investors should consider this a routine profit-taking event rather than a strong indicator of future company performance, and thus a 'hold' recommendation is appropriate pending further fundamental analysis.

Keywords

Wave Life Sciences, WVE, Insider Trading, Form 4, Stock Sale, Option Exercise, Director Transaction, 10b5-1 Plan